OTLC — Oncotelic Therapeutics Balance Sheet
0.000.00%
- $43.28m
- $55.83m
- 12
- 26
- 91
- 37
Annual balance sheet for Oncotelic Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.474 | 0.569 | 0.241 | 0.17 | 0.086 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.02 | 0.02 | 0.02 | 0.019 | 0.019 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.616 | 0.627 | 0.303 | 0.272 | 0.134 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.01 | 0 | — | — | — |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 23.7 | 23.6 | 36.1 | 30 | 26.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.2 | 15.5 | 16.9 | 16.5 | 19.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 11.9 | 15.7 | 16.7 | 17.9 | 18.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 11.8 | 7.96 | 19.4 | 12.1 | 8.25 |
| Total Liabilities & Shareholders' Equity | 23.7 | 23.6 | 36.1 | 30 | 26.7 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |